Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States

References

• Menter A, Griffiths CE. Current and future management of psoriasis. Lancet. 2007;370:272–284.
   PubMed Web of Science ®Google Scholar
• Stein KR, Pearce DJ, Feldman SR. The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. Semin Cutan Med Surg. 2005;24:52–57.
   PubMed Web of Science ®Google Scholar
• Pearce DJ, Thomas CG, Fleischer AB Jr, Feldman SR. The cost of psoriasis therapies: Considerations for therapy selection. Dermatol Nurs. 2004;16:421–428.
   PubMedGoogle Scholar
• Nelson AA, Pearce DJ, Fleischer AB Jr, Balkrishnan R, Feldman SR. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol. 2008;58:125–135.
   PubMed Web of Science ®Google Scholar
• Pearce DJ, Nelson AA, Fleischer AB, Balkrishnan R, Feldman SR. The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies. J Dermatol Treat. 2006;17:29–37.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Garton R, Averett W, Balkrishnan R, Vallee J. Strategy to manage the treatment of severe psoriasis: Considerations of efficacy, safety and cost. Expert Opin Pharmacother. 2003;4:1525–1533.
   PubMed Web of Science ®Google Scholar
• Detsky AS, Laupacis A. Relevance of cost-effectiveness analysis to clinicians and policy makers. JAMA. 2007;298:221–224.
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Rosen AB, Weinstein MC. Medicare and cost-effectiveness analysis. N Engl J Med. 2005;353:1516–1522.
   PubMed Web of Science ®Google Scholar
• Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. 1st ed. USA: Oxford University Press; 1996.
   Google Scholar
• Sterry W, Barker J, Boehncke WH, Bos JD, Chimenti S, Christophers E, Biological therapies in the systemic management of psoriasis: International consensus conference. Br J Dermatol. 2004;151:3–17.
   PubMed Web of Science ®Google Scholar
• Callen JP, Krueger GG, Lebwohl M, McBurney EI, Mease P, Menter A, AAD consensus statement on psoriasis therapies. J Am Acad Dermatol. 2003;49:897–899.
   PubMed Web of Science ®Google Scholar
• Torrance GW, Feeny D. Utilities and quality-adjusted life-years. Int J Technol Assess Health Care. 1989;5:559–575.
   PubMedGoogle Scholar
• Fredriksson T, Pettersson U. Severe psoriasis: Oral therapy with a new retinoid. Dermatologica. 1978;157:238–244.
   PubMedGoogle Scholar
• Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, Efficacy and safety results from the Comparative Study of Adalimumab (HUMIRA) Versus Methotrexate Versus Placebo in Psoriasis Patients (CHAMPION). Br J Dermatol. 2008;158:558–566.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG, Leonardi C, Toth D, Menter A, Kang S, Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55:598–606.
   PubMed Web of Science ®Google Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095–1108.
   PubMed Web of Science ®Google Scholar
• Sizto S, Bansback N, Feldman S, Willian M, Anis A. Economic evaluation of systemic therapies for moderate to severe psoriasis. Br J Dermatol. 2009;160:1264–1272.
   PubMed Web of Science ®Google Scholar
• Bansback N, Sizto S, Sun H, Feldman S, Willian M, Anis A. Efficacy of systemic treatments for moderate to severe plaque psoriasis: Systematic review and meta-analysis. Dermatology. 2009;219:209–218.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration [cited 2007 December 25]. Available from: http://www.fda.gov/
   Google Scholar
• Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Etanercept and efalizumab for the treatment of psoriasis: A systematic review. Health Technol Assess. 2006;10:1–233.
   PubMed Web of Science ®Google Scholar
• Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23:3105–3124.
   PubMed Web of Science ®Google Scholar
• Analy$ource. Marketing analytics and business insights, Abbott Laboratories [cited 2007 August 24]. Available from: www.analysource.com
   Google Scholar
• Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005;152:861–867.
   PubMed Web of Science ®Google Scholar
• Alefacept [package insert]. Astellas Pharma US, Inc., Deerfield, IL; 2007 [cited 2007 August 23]. Available from: http://www.astellas.us/docs/amevive.pdf
   Google Scholar
• Efalizumab [package insert]. Genentech Inc., South San Francisco, CA; 2007 [cited 2007 August 23]. Available from: http://www.gene.com/gene/products/information/pdf/raptiva-prescribing.pdf
   Google Scholar
• Etanercept [package insert]. Immunex Corp., Thousand Oaks, CA; 2007 [cited 2007 August 23]. Available from: http://www.enbrel.com/pdf/enbrel_pi.pdf
   Google Scholar
• Infliximab [package insert]. Centocor Inc., Malvern, PA; 2007 [cited 2007 August 23]. Available from: http://www.remicade.com/remicade/assets/HCP_PPI.pdf
   Google Scholar
• Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106–115.
   PubMed Web of Science ®Google Scholar
• Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial. Lancet. 2001;357:1842–1847.
   PubMed Web of Science ®Google Scholar
• Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56:31.e1–15.
   Web of Science ®Google Scholar
• Stern RS. PUVA follow-up study. Inpatient hospital care for psoriasis: A vanishing practice in the United States. J Am Acad Dermatol. 2003;49:445–450.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health & Human Services, Agency for Healthcare Research and Quality- Health Cost & Utilization Project (HCUP). 2005 National and Regional Statistics on Hospital Stays from the NIS [cited 2007 August 21]. Available from: http://www.remicade.com/remicade/assets/HCP_PPI.pdf
   Google Scholar
• US Department of Labor, Bureau of Labor Statistics. National Compensation Survey: Occupational Wages in the United States, June 2006 [cited 2007 August 23]. Available from: http://www.bls.gov/ncs/ocs/sp/ncb10910.pdf
   Google Scholar
• Javitz HS, Ward MM, Farber E, Nail L, Vallow SG. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol. 2002;46:850–860.
   PubMed Web of Science ®Google Scholar
• Drummond M, O'Brien B, Stoddart G, Torrance G. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press; 1997,131–135
   Google Scholar
• Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life-year: In search of a standard. Med Decis Making. 2000;20:332–342.
   PubMed Web of Science ®Google Scholar
• Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: How are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7:518–528.
   PubMed Web of Science ®Google Scholar
• O'Hagan A, McCabe C, Akehurst R, Brennan A, Briggs A, Claxton K, Incorporation of uncertainty in health economic modelling studies. Pharmacoeconomics. 2005;23:529–536.
   PubMed Web of Science ®Google Scholar
• Academy of Managed Care Pharmacy. A format for submission of clinical and economic data in support of formulary consideration by health care systems in the United States. The AMCP Format for Formulary Submissions, Version 2.1 [cited 2007 October 1]. Available from: http://www.fmcpnet.org/index.cfm?pl=ADEE1897
   Google Scholar
• Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23:3105–3124.
   PubMed Web of Science ®Google Scholar
• Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: Empirical evidence from published meta-analyses. BMJ. 2003;326:472.
   PubMed Web of Science ®Google Scholar
• Costanzo A, Papoutsaki M, Mazzotta A, Gramiccia T, Chimenti S. Previous biological therapies influence the rate of response to etanercept in chronic plaque psoriasis. Br J Dermatol. 2006;154: Abstract FC-20.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51:534–542.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Kimball AB, Mostow EN, Chiou CF, Patel V, Xia HA, Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: Continuous versus interrupted treatment. Value Health. 2008;11:400–407.
   PubMed Web of Science ®Google Scholar
• Schmitt JM, Ford DE. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology. 2006;213:102–110.
   PubMed Web of Science ®Google Scholar
• Pearce DJ, Singh S, Balkrishnan R, Kulkarni A, Fleischer AB, Feldman SR. The negative impact of psoriasis on the workplace. J Dermatolog Treat. 2006;17:24–28.
   PubMed Web of Science ®Google Scholar
• Schoffski O, Augustin M, Prinz J, Rauner K, Shubert E, Sohn S, Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: A multi-center study. J Dtsch Dermatol Ges. 2007;5:209–218.
   PubMedGoogle Scholar
• Richards HL, Fortune DG, Griffiths CE, Main CJ. The contribution of perceptions of stigmatisation to disability in patients with psoriasis. J Psychosom Res. 2001;50:11–15.
   PubMed Web of Science ®Google Scholar